SigIQGAP3NW expression also serves as an accurate predictor of poor responses to chemotherapy, and given the strong association of this gene signature with the chemotherapy targets PLK1 and TOP1, targeting PLK1 and TOP1 may be a strategy to treat cancer patients expressing high levels of the signature SigIQGAP3NW, including high levels of IQGAP3 and RELT. This evidence concerns the gene TOP1 and cancer.